Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.

Trial Details

NCT ID
NCT07096778
Phase
PHASE2
Sponsor
CellCentric Ltd.
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Inobrodib
  • Pomalidomide
  • Dexamethasone
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Tampa, Florida, United States|27.94752,-82.45843
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Bethesda, Maryland, United States|38.98067,-77.10026
  • St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

  • Male or female ≥18 years of age
  • Prior diagnosis of MM as defined according to IMWG criteria and relapsed or refractory to the last line of therapy
  • Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2
  • Adequate hematological, renal and hepatic function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →